Furthermore, triple-negative breast cancer patients face resistance to the drug trastuzumab by the active involvement of Polyadenylate-binding protein 1 (Pabpc1), expression of which is induced by overexpression of SNHG1463. Here, PABPC1 is linked to triple-negative breast carcinoma.